Literature DB >> 22155801

Total knee arthroplasty with NexGen legacy posterior stabilized.

M Zimlitski1, K K Bhokray, B M Rajan, L Nachkebia, G Loria.   

Abstract

Total knee arthroplasty (TKA) has been primarily devised for pain free range of movement near physiological demands and even take part in sports and leisure interests along with day to day activities. Therefore we conducted an assessment on the performance of our patients after 5 years of followup. Total of 94 patients ranging from an age group of 38 to 75 years with pathologies of osteoarthritis, rheumatoid arthritis and post traumatic arthritis were subjected to implantation in our institution and included in this restrospective study. All patients were implanted with NexGen Legacy Posterior Stabilisied (LPS) system. The results have been drawn on the basis of the clinical performance and radiographic analysis with a follow up of upto 5 years. Knee society score increase from Preoperatively 60 to postoperatively 85, Knee functional score increase from preoperatively 55 to postoperatively 100. No cases of patella clunk syndrome or patella dislocation were observed in our patients. The final clinical results of operative treatment with Nexgen LPS system after 5 years of follow-up of patients corresponding to daily approved International scoring system. All of this indicates the advantages of this system comparing to its other daily analogues.

Entities:  

Mesh:

Year:  2011        PMID: 22155801

Source DB:  PubMed          Journal:  Georgian Med News        ISSN: 1512-0112


  2 in total

1.  Analysis of differences in bone removal during femoral box osteotomy for primary total knee arthroplasty.

Authors:  Angelo Graceffa; Pier Francesco Indelli; Kaitlyn Basnett; Massimiliano Marcucci
Journal:  Joints       Date:  2014-07-08

2.  Primary posterior stabilized total knee arthroplasty: analysis of different instrumentation.

Authors:  Pier Francesco Indelli; Massimiliano Marcucci; Angelo Graceffa; Sophie Charlton; Leonardo Latella
Journal:  J Orthop Surg Res       Date:  2014-07-19       Impact factor: 2.359

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.